Claims for Patent: 9,283,195

Summary for Patent: 9,283,195

Title:	Methods used to characterize and treat glioblastoma
Abstract:	The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
Inventor(s):	Tran; Nhan (Phoenix, AZ)
Assignee:	The Translational Genomics Research Institute (Phoenix, AZ)
Application Number:	14/595,423
Patent Claims:	1. A method of treating a patient with glioblastoma, the method comprising the steps of: (a) sensitizing the patient to a treatment by reducing an expression level of a marker selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO. 2; and (b) administering a therapeutically effective amount of the treatment to the patient. 2. The method of claim 1, wherein the glioblastoma comprises invasive glioblastoma. 3. The method of claim 1, wherein the treatment comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, temozolimide and bevacizumab. 4. The method of claim 1, wherein reducing the expression level of the marker is enabled by small interfering RNAs targeting the nucleic acid encoding for the marker. 5. The method of claim 4, wherein the small interfering RNAs comprise oligonucleotides. 6. A method of characterizing a glioblastoma tumor as invasive and sensitizing the invasive glioblastoma tumor for treatment, the method comprising the steps of: (a) adding a first reagent capable of binding to a marker selected from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2 to a mixture comprising a sample of the glioblastoma tumor; (b) subjecting the mixture to conditions that allow detection of binding of the reagent to the marker; (c) classifying the glioblastoma tumor as invasive when the binding of the reagent to the marker is increased compared to a control sample; and (d) reducing an expression level of the marker to sensitize the invasive glioblastoma tumor to a treatment. 7. The method of claim 6, wherein sensitizing the invasive glioblastoma tumor induces apoptosis in at least a portion of cells of the tumor upon administration of the treatment. 8. The method of claim 6 and further comprising administering a therapeutically effective amount of the treatment to the patient. 9. The method of claim 8, wherein the treatment comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, temozolimide and bevacizumab. 10. The method of claim 6, wherein the sample is selected from the group consisting of brain tissues, fluid samples, and single cells. 11. The method of claim 6, wherein reducing the expression level of the marker is enabled by small interfering RNAs targeting the nucleic acid encoding for the marker. 12. The method of claim 11, wherein the small interfering RNAs comprise oligonucleotides. 13. A method of treating a patient with invasive glioblastoma, the method comprising the steps of: (a) sensitizing the patient to a treatment by reducing an expression level of at least one of the following: a marker selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO. 2 and Proline-rich tyrosine kinase 2 (Pyk2); and (b) administering a therapeutically effective amount of the treatment to the patient. 14. The method of claim 13, wherein the treatment comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, temozolimide and bevacizumab. 15. The method of claim 13, wherein reducing the expression level of the marker or Pyk2 is enabled by small interfering RNAs targeting the nucleic acid encoding for the marker. 16. The method of claim 15, wherein the small interfering RNAs comprise oligonucleotides. 17. The method of claim 13, wherein the treatment is temozolimide. 18. The method of claim 13, wherein the sensitizing step comprises reducing the expression level of the marker and Pyk2.

Details for Patent 9,283,195

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-10-23